21 Community Clusters
12 in Zambia / 9 in South Africa
Average of approx. 55,000 individuals in each cluster
Approximately 600,000 total adults across all communities

Randomization

Arm A
Clusters: 4 Zambia / 3 South Africa

Intervention
Combination prevention including:
• Universal household-based testing
• Active linkage to care
• Immediate ART eligibility

Evaluation
Population Cohort A
One adult from each of 2,500 randomly selected households in each cluster

Health Centre Data A
Routinely collected data from Health Centres in the community

CHiPs Data A
Data collected from community members during household visits

Arm B
Clusters: 4 Zambia / 3 South Africa

Intervention
Combination prevention including:
• Universal household-based testing
• Active linkage to care
• ART eligibility according to national guidelines

Evaluation
Population Cohort B
One adult from each of 2,500 randomly selected households in each cluster

Health Centre Data B
Routinely collected data from Health Centres in the community

CHiPs Data B
Data collected from community members during household visits

Arm C
Clusters: 4 Zambia / 3 South Africa

Standard of Care
Control Arm:
• Existing prevention & testing services and referral for care
• ART eligibility according to national guidelines

Evaluation
Population Cohort C
One adult from each of 2,500 randomly selected households in each cluster

Health Centre Data C
Routinely collected data from Health Centres in the community

Primary Outcome Measure
• HIV incidence measured over 3 years in Population Cohort (from Arms A, B and C)

Secondary Outcome Measures
• Population Cohort: HIV incidence measured over 1st, 2nd, and 3rd years, HSV-2 incidence, sexual risk behaviour, community VL*, viral suppression (ART patients)*, drug resistance (ART patients with detectable VL)*
• Population Cohort and Health Centre Data: ART Adherence, HIV disease progression and death, ART toxicity, HIV stigma
• Health Centre Data: TB notification and TB mortality rates
• Population Cohort, Health Centre Data, CHiPs Data: uptake of PMTCT, uptake of male circumcision, ART screening and uptake, uptake of HIV testing and retesting, time between diagnosis and initiation of care

* Subject to funding for these assays.